EGFR and non-small cell lung carcinoma: The phase III EXCLAIM-2 trial assessed the efficacy of first-line mobocertinib compared to platinum-based chemotherapy in patients with NSCLC harboring EGFR exon 20 insertions and who had not received prior therapy [34].